Gulbrandsen Technologies is proud to announce its participation in two pivotal global life sciences events in late 2025: the DCVMN International Annual General Meeting in Bali, Indonesia, and CPHI Frankfurt in Germany. These engagements underscore our dedication to providing cutting-edge, reliable chemical solutions for the pharmaceutical and vaccine industries worldwide.
DCVMN International: Building a Resilient Vaccine Ecosystem
October 29–31, 2025 | Bali, Indonesia
Our presence begins in Bali at the 26th Developing Countries Vaccine Manufacturers Network (DCVMN) AGM, co-hosted with PT Bio Farma. The theme, “Advancing innovation and building a resilient vaccine ecosystem for a safer world,” perfectly aligns with our strategic vision. This event is vital for connecting with global vaccine manufacturers, health institutions, and partners focused on strengthening vaccine self-reliance in developing nations.
Gulbrandsen Technologies will spotlight our expertise in Adjuvants. These essential components play a critical role in enhancing vaccine efficacy and immune response, often allowing for dose-sparing—a crucial factor in scaling up global vaccine production and improving equitable access. We look forward to engaging in high-level discussions on scientific progress, regulatory harmonization, and capacity building to ensure our advanced solutions support a robust, future-ready vaccine supply chain.
CPHI Frankfurt: At the Heart of the Pharma Supply Chain
October 28–30, 2025 | Messe Frankfurt, Germany
Following Bali, Gulbrandsen Technologies will join the world’s largest pharmaceutical exhibition, CPHI Frankfurt. This massive trade show, which attracts over 62,000 attendees and 2,400 exhibitors from over 160 countries, is the ultimate meeting place for the global pharma supply chain.
Our focus at CPHI will be on Sucralfate, a highly effective and trusted excipient foundational to many modern gastrointestinal formulations. Sucralfate exemplifies our commitment to supplying the pharmaceutical industry with high-quality, proven materials. We will also present our broader portfolio of high-quality fine chemicals and excipients, demonstrating our capacity to support diverse drug development and manufacturing needs.
Both DCVMN International and CPHI Frankfurt are invaluable opportunities to explore collaborations, meet industry leaders, and reinforce our role as a trusted partner in global health. We are excited to continue building a healthier future through chemistry and innovation alongside our peers.